Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio De Ponti

Showing results (1-10 of 197) with videos related to

Pageof 20
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Methylnaltrexone ProgenicsFabrizio De Ponti
Recenti Progressi in Medicina|February 20, 2002
[Physiopathology of the enteric nervous system: recent advances and clinical implications]Fabrizio De Ponti
Frontiers in Pharmacology|February 5, 2013
Drug development for the irritable bowel syndrome: current challenges and future perspectivesFabrizio De Ponti
Heart (British Cardiac Society)|November 29, 2017
Liver injury with direct-acting anticoagulants: has the fog cleared?Emanuel Raschi, Fabrizio De Ponti
World Journal of Hepatology|July 14, 2015
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing riskEmanuel Raschi, Fabrizio De Ponti
Expert Opinion on Drug Metabolism & Toxicology|January 7, 2014
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndromeEmanuel Raschi, Fabrizio De Ponti
Pharmaceutics|March 6, 2021
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical PeculiaritiesMilo Gatti, Fabrizio De Ponti
Giornale Italiano Di Cardiologia (2006)|April 28, 2012
[Between guidelines and regulatory decisions: the odyssey of dronedarone]Fabrizio De Ponti, Alessandro Mugelli
World Journal of Hepatology|January 21, 2017
Drug-induced liver injury: Towards early prediction and risk stratificationEmanuel Raschi, Fabrizio De Ponti
Internal and Emergency Medicine|December 14, 2011
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncologyEmanuel Raschi, Fabrizio De Ponti
Pageof 20

Showing results (1-10 of 197) with videos related to

Sort By:
Pageof 20
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Methylnaltrexone ProgenicsFabrizio De Ponti
Recenti Progressi in Medicina|February 20, 2002
[Physiopathology of the enteric nervous system: recent advances and clinical implications]Fabrizio De Ponti
Frontiers in Pharmacology|February 5, 2013
Drug development for the irritable bowel syndrome: current challenges and future perspectivesFabrizio De Ponti
Heart (British Cardiac Society)|November 29, 2017
Liver injury with direct-acting anticoagulants: has the fog cleared?Emanuel Raschi, Fabrizio De Ponti
World Journal of Hepatology|July 14, 2015
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing riskEmanuel Raschi, Fabrizio De Ponti
Expert Opinion on Drug Metabolism & Toxicology|January 7, 2014
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndromeEmanuel Raschi, Fabrizio De Ponti
Pharmaceutics|March 6, 2021
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical PeculiaritiesMilo Gatti, Fabrizio De Ponti
Giornale Italiano Di Cardiologia (2006)|April 28, 2012
[Between guidelines and regulatory decisions: the odyssey of dronedarone]Fabrizio De Ponti, Alessandro Mugelli
World Journal of Hepatology|January 21, 2017
Drug-induced liver injury: Towards early prediction and risk stratificationEmanuel Raschi, Fabrizio De Ponti
Internal and Emergency Medicine|December 14, 2011
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncologyEmanuel Raschi, Fabrizio De Ponti
Pageof 20